Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial to compare progression-free survival in patients with metastatic colorectal cancer receiving irinotecan in combination with capecitabine or fluorouracil/leucovorin and bevacizumab (XELIRI-bevacizumab vs FOLFIRI-bevacizumab) as first-line treatment. A study of the Hellenic Cooperative Oncology Group (HeCOG)

Trial Profile

Randomized phase III trial to compare progression-free survival in patients with metastatic colorectal cancer receiving irinotecan in combination with capecitabine or fluorouracil/leucovorin and bevacizumab (XELIRI-bevacizumab vs FOLFIRI-bevacizumab) as first-line treatment. A study of the Hellenic Cooperative Oncology Group (HeCOG)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2012 Status changed from active, no longer recruiting to completed, based on final results published in BMC Cancer.
    • 29 Oct 2012 Primary endpoint 'Progression-free-survival-rate' has not been met, based on final results published in BMC Cancer.
    • 29 Jun 2012 Final results published in the BMC Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top